TNF inhibitors for treatment of bowel disease not linked with increased risk of cancer

June 17, 2014, The JAMA Network Journals

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

Tumor necrosis factor α (TNF-α) antagonists are drugs that have been shown to be beneficial in reducing the inflammation in inflammatory diseases such as rheumatoid arthritis, and (IBD) (Crohn disease and ulcerative colitis). The therapeutic benefits of TNF-α antagonists must be weighed against the potential for adverse effects, including a possible increased risk of cancer. "Therefore, long-term observational studies of consequences of treatment with TNF-α antagonists are needed," the authors write.

Nynne Nyboe Andersen, M.D., of the Statens Serum Institut, Copenhagen, and colleagues studied cancer rates in patients with IBD exposed to TNF-α antagonists, as compared with patients with IBD not exposed to these drugs. The study included 56,146 patients (15 years or older) with IBD identified in the National Patient Registry of Denmark (1999-2012), of whom 4,553 (8.1 percent) were treated with TNF-α antagonists. Cancer cases were identified in the Danish Cancer Registry.

In total, 3,465 patients with IBD unexposed to TNF-α antagonists (6.7 percent) and 81 exposed to TNF-α antagonists (1.8 percent; median follow-up, 3.7 years) developed cancer. The study results indicated that exposure to TNF-α antagonists was not associated with an increased overall cancer risk. In addition, no site-specific cancers were observed in significant excess.

The authors note that because of the relatively small sample size and the small number of cancer cases in this study, statistical power was limited in analyses of site-specific and also for analyses stratified according to certain criteria, such as duration of follow-up.

"An increased risk of malignancy in the long term or with increasing number of cumulative doses of TNF-α antagonists cannot be excluded, and continuous follow-up of exposed is needed."

Explore further: Use of certain therapies for inflammatory diseases does not appear to increase risk of shingles

More information: DOI: 10.1001/jama.2014.5613

Related Stories

Use of certain therapies for inflammatory diseases does not appear to increase risk of shingles

March 5, 2013
Although patients with rheumatoid arthritis (RA) have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that ...

Biological agents for rheumatoid arthritis associated with increased skin cancer risk

September 8, 2011
Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Use of biologic therapies for inflammatory diseases does not appear to increase risk of shingles

April 19, 2013
Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment ...

Adhesion molecule shows promise for treating colitis

April 29, 2014
The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease (IBD) as well as preventing colitis-associated colorectal cancer, say scientists. ...

Frequently used biologic agents might cause acute liver injury

April 29, 2013
A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Low vitamin D levels tied to increased cancer risk in IBD

May 6, 2014
(HealthDay)—Low plasma levels of 25-hydroxyvitamin D (25[OH]D) are associated with an increased risk of cancer in patients with inflammatory bowel diseases (IBD), according to a study published in the May issue of Clinical ...

Recommended for you

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

ALinC
not rated yet Jun 18, 2014
This just isn't a good article. The number of exposed patients vs not exposed patients is not even close to a balanced number, therefore making this study something close to worthless.
I'd tell anyone considering getting these drugs, to thoroughly research and know what these drugs do to the body before agreeing to the treatment. Most doctors have gotten very comfortable treating their patients with these chemicals. They prob. won't tell you much about the 3 pages of potential side-effects either. I've also noticed that doctors may not even take genetics into consideration to assess if the patient is a good candidate for this type of treatment. These drugs are not appropriate treatments for everyone. Know the facts about these drugs by researching things yourself.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.